Case report demonstrates excellent outcomes with topical ruxolitinib cream in childhood nail lichen planus, suggesting new treatment options.
The role of oral JAK inhibitors in the treatment of nail lichen planus (NLP) has recently been reported, but there have been no literature reports on the treatment of NLP with topical Janus kinase (JAK) inhibitor. We present, for the first time, a preliminary clinical experience with topical ruxolitinib cream, a JAK inhibitor, in a child with NLP. The remarkable results suggest topical ruxolitinib cream may be a potential treatment option for NLP.
No takes yet. Share an insight, caveat, or question.
Sheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: